Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus plantarum OLL2712
- Development stage
- Unknown
- Lead developer
- Meiji
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Lactobacillus plantarum OLL2712** is a specific strain of *Lactobacillus plantarum* developed by Meiji for use as an orally administered probiotic or paraprobiotic functional food ingredient. In the published human trial context provided, it was administered as **heat-treated bacterial cells** in yogurt and was investigated for **obesity-related metabolic dysfunction** in overweight adults. Its proposed mechanism is **immunometabolic modulation in the gut**, with reported suppression of chronic low-grade inflammation, including reduction of inflammatory markers such as IL-6, and downstream improvement in glucose handling and abdominal fat accumulation. This is best characterized as a microbiome-derived nutritional or functional-food intervention rather than a conventional pharmaceutical product.
- Other names
- Lactobacillus plantarum OLL2712heat-treated Lactobacillus plantarum OLL2712heat-treated OLL2712
02
Targets
IL10 (Interleukin-10)CLEC4E (Macrophage-inducible C-type lectin receptor)MYD88 (Myeloid differentiation primary response protein MyD88)TLR2 (Toll-like Receptor 2)IL-6 (Interleukin 6)
Beyond the preview
Go deeper on Lactobacillus plantarum OLL2712.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus plantarum OLL2712.